Drugs in Dev. Otolaryngology (Ear, Nose, Throat)
Preclinical
France 
Lead Product(s) : OTOF-GT
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Preclinical
Sponsor : Institut Pasteur
Deal Size : Undisclosed
Deal Type : Partnership
Sensorion Extends Partnership with Institut Pasteur for Hearing Disorder Gene Therapies
Details : Sensorion and Institut Pasteur are developing gene therapies, including SENS-501 for otoferlin-related deafness and GJB2-GT for GJB2 mutation-related hearing loss.
Product Name : OTOF-GT
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
January 05, 2024
Lead Product(s) : OTOF-GT
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Preclinical
Sponsor : Institut Pasteur
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : OTOF-GT
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SENS-501 is an adeno-associated vector-based gene therapy for the autosomal recessive non-syndromic Deafness 9. It is being investigated in preclinical stage for DFNB9.
Product Name : OTOF-GT
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
February 02, 2023
Lead Product(s) : OTOF-GT
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OTOF-GT
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OTOF-GT is targeting deafness caused by a mutation of the gene encoding for otoferlin, and hearing loss related to mutation in GJB2 gene to potentially address important hearing loss segments in adults and children (GJB2-GT).
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
October 06, 2022
Lead Product(s) : OTOF-GT
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OTOF-GT
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Sensorion Announces Positive Preliminary Preclinical Data From Its Otoferlin Gene Therapy Program
Details : In vivo experiments conducted safely in non-human primates show promising preliminary data on inner ear tissue tropism and the achievement of a high transduction rate efficiency post Otoferlin Gene Therapy.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
June 09, 2020
Lead Product(s) : OTOF-GT
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
